TCR-Engineered T-Cell Therapy: Peptide-MHC Recognition

TCR-engineered T-cell therapy modifies a patient's own T cells with a designer T-cell receptor that recognises one specific peptide fragment presented in an MHC-I molecule on the tumor surface — a fundamentally different recognition rule from CAR-T's direct surface-antigen grip. This simulator renders a 3D field of tumor cells and engineered T cells: T cells patrol the tissue, dock on nearby tumor cells to form an immunological synapse, and a Hill-type avidity model — driven by receptor affinity, peptide-MHC density, and clinically-observed MHC-I downregulation escape — decides whether that contact kills the tumor cell or fails. Adjust the receptor's dissociation constant, the tumor's antigen presentation, the fraction of MHC-low escape variants, and the size of the infused T-cell dose, and watch the live kill rate and immune-escape readouts respond in real time.